Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors
Bio-Techne (NASDAQ: TECH) has appointed Dr. Amy E. Herr to its Board of Directors, effective February 1, 2025. Dr. Herr, who will serve on the Board's Science & Technology Committee, is currently a Chancellor's Professor of Bioengineering at UC Berkeley and Vice President of the Chan Zuckerberg Biohub Network.
Dr. Herr brings significant experience in bioengineering and leadership roles, including serving as Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub and on the National Advisory Council for Biomedical Imaging and Bioengineering. Notably, she was a co-founder of Zephyrus Biosciences, which Bio-Techne acquired in 2016.
This appointment completes a two-year board succession process, with Dr. Herr succeeding Dr. Roeland Nusse, who will retire later in 2025. The company's leadership highlighted her deep biological and engineering expertise as particularly valuable for Bio-Techne's strategic direction and growth in proteomic analytical instruments.
Bio-Techne (NASDAQ: TECH) ha nominato la Dott.ssa Amy E. Herr nel suo Consiglio di Amministrazione, con effetto dal 1 febbraio 2025. La Dott.ssa Herr, che sarà membro del Comitato Scienza e Tecnologia del Consiglio, è attualmente Professore Cancelliere di Bioingegneria presso UC Berkeley e Vice Presidente della Chan Zuckerberg Biohub Network.
La Dott.ssa Herr porta un'esperienza significativa in bioingegneria e ruoli di leadership, avendo ricoperto il ruolo di Direttore Esecutivo Fondatore dell'Bakar BioEnginuity Hub di UC Berkeley e facendo parte del Consiglio Consultivo Nazionale per l'Imaging Biomedico e la Bioingegneria. È importante notare che è stata co-fondatrice di Zephyrus Biosciences, che Bio-Techne ha acquisito nel 2016.
Questa nomina completa un processo di successione del consiglio della durata di due anni, con la Dott.ssa Herr che succede al Dott. Roeland Nusse, il quale si ritirerà alla fine del 2025. I leader dell'azienda hanno sottolineato la sua profonda esperienza biologica e ingegneristica come particolarmente preziosa per la direzione strategica e la crescita di Bio-Techne negli strumenti analitici proteomici.
Bio-Techne (NASDAQ: TECH) ha nombrado a la Dra. Amy E. Herr en su Junta Directiva, con efecto a partir del 1 de febrero de 2025. La Dra. Herr, que formará parte del Comité de Ciencia y Tecnología de la Junta, es actualmente Profesora Canciller de Bioingeniería en UC Berkeley y Vicepresidenta de la Chan Zuckerberg Biohub Network.
La Dra. Herr aporta una experiencia significativa en bioingeniería y roles de liderazgo, habiendo sido Directora Ejecutiva Fundadora del Bakar BioEnginuity Hub de UC Berkeley y miembro del Consejo Asesor Nacional de Imágenes Biomédicas y Bioingeniería. Vale la pena mencionar que fue cofundadora de Zephyrus Biosciences, que Bio-Techne adquirió en 2016.
Este nombramiento completa un proceso de sucesión de dos años en la junta, con la Dra. Herr sucediendo al Dr. Roeland Nusse, quien se retirará a finales de 2025. Los líderes de la empresa destacaron su profunda experiencia biológica y de ingeniería como particularmente valiosa para la dirección estratégica y el crecimiento de Bio-Techne en los instrumentos analíticos proteómicos.
Bio-Techne (NASDAQ: TECH)는 2025년 2월 1일부터 유효한 이사회에 드. 에이미 E. 헤르(DR. Amy E. Herr)를 임명했습니다. 이사회 과학 및 기술 위원회에서 활동하는 헤르 박사는 현재 UC 버클리에서 생명공학 총장 교수로 재직 중이며, 챈 저커버그 바이오허브 네트워크의 부회장입니다.
헤르 박사는 UC 버클리의 박라 바이오엔지니어링 허브의 창립 전무이사로 근무하고, 생물 의학 이미징 및 생명공학과 관련된 국가 자문 위원회에서 활동하는 등 생명공학 및 리더십 역할에서 상당한 경험을 가지고 있습니다. 특히, 그녀는 Bio-Techne가 2016년에 인수한 제퍼러 바이오사이언스의 공동 창립자였습니다.
이번 임명은 2년에 걸친 이사회 승계 과정을 완료한 것으로, 헤르 박사가 2025년 말에 퇴임할 로엘란드 너스 박사를 대리하게 됩니다. 회사의 리더들은 생물학 및 공학 분야에서 그녀의 깊이 있는 전문 지식이 Bio-Techne의 전략적 방향과 단백질 분석 기구의 성장에 특히 유용하다고 강조했습니다.
Bio-Techne (NASDAQ: TECH) a nommé Dr. Amy E. Herr à son conseil d'administration, avec effet le 1er février 2025. Dr. Herr, qui siégera au Comité de la science et de la technologie du conseil, est actuellement professeure chancelier en bio-ingénierie à l'UC Berkeley et vice-présidente du réseau Chan Zuckerberg Biohub.
Dr. Herr apporte une expérience significative en bio-ingénierie et dans des rôles de direction, ayant été directrice exécutive fondatrice du Bakar BioEnginuity Hub de l'UC Berkeley et membre du Conseil consultatif national sur l'imagerie biomédicale et la bio-ingénierie. Il convient de noter qu'elle a été co-fondatrice de Zephyrus Biosciences, que Bio-Techne a acquis en 2016.
Cette nomination finalize un processus de succession de deux ans, Dr. Herr succédant à Dr. Roeland Nusse, qui prendra sa retraite à la fin de 2025. Les dirigeants de l'entreprise ont souligné que son expertise biologique et en ingénierie, approfondie, est particulièrement précieuse pour l'orientation stratégique et la croissance de Bio-Techne dans les instruments d'analyse protéomique.
Bio-Techne (NASDAQ: TECH) hat Dr. Amy E. Herr in seinen Vorstand berufen, der am 1. Februar 2025 in Kraft tritt. Dr. Herr, die im Wissenschafts- und Technologiekomitee des Vorstands tätig sein wird, ist derzeit Kanzlerprofessorin für Bioengineering an der UC Berkeley und Vizepräsidentin des Chan Zuckerberg Biohub-Netzwerks.
Dr. Herr bringt umfassende Erfahrungen in der Bioengineering und in Führungsrollen mit, darunter die Wissenschaft als Gründungsdirektorin des Bakar BioEnginuity Hub an der UC Berkeley und die Mitgliedschaft im Nationalen Beratungsausschuss für biomedizinische Bildgebung und Bioengineering. Besonders bemerkenswert ist, dass sie Mitgründerin von Zephyrus Biosciences war, das Bio-Techne 2016 erworben hat.
Diese Ernennung beendet einen zweijährigen Nachfolgeprozess im Vorstand, wobei Dr. Herr Dr. Roeland Nusse nachfolgt, der Ende 2025 in den Ruhestand gehen wird. Die Führung des Unternehmens hob ihre tiefgreifende biologische und ingenieurtechnische Expertise hervor, die für die strategische Ausrichtung und das Wachstum der proteomischen Analyseinstrumente von Bio-Techne besonders wertvoll ist.
- Strategic board appointment bringing expertise in bioengineering and proteomics
- Previous connection to Bio-Techne through Zephyrus Biosciences acquisition
- Completion of planned board succession process ensuring leadership continuity
- None.
Dr. Herr is a Chancellor's Professor of Bioengineering at the University of
Dr. Herr's appointment completes a two-year process by the Board of Directors to identify and appoint successors to retiring directors Randy Steer, who retired in 2024, and Dr. Roeland Nusse, who will be retiring later in 2025. Dr. Herr will succeed Dr. Roeland Nusse.
"Dr. Herr's deep biological and engineering experience are an ideal fit for our board and the strategic direction of the Company," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "We are elated to add someone with Dr. Herr's credentials to our board."
"We are pleased to welcome Dr. Herr to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne. "She brings tremendous scientific experience to Bio-Techne. For example, Dr. Herr's extensive bioengineering background brings an important skillset as the Company continues to grow its proteomic analytical instrument business."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-appoints-dr-amy-e-herr-to-board-of-directors-302367293.html
SOURCE Bio-Techne Corporation
FAQ
When will Dr. Amy E. Herr join Bio-Techne (TECH) Board of Directors?
Which committee will Dr. Herr serve on Bio-Techne's (TECH) board?
Who is Dr. Amy E. Herr replacing on Bio-Techne's (TECH) board?
What is Dr. Herr's connection to Bio-Techne (TECH)?
How long did Bio-Techne's (TECH) board succession process take?
